This example shows a report table, trial design, and results data for the in vitro Neutral Red Uptake Cytotoxicity Assay neutral red uptake (NRU) cytotoxicity assay in example study 123.
| Expand |
|---|
| title | Sample from Report Table |
|---|
|
The following shows example data for study 123 in a report table. This report includes summary statistics (i.e.g. Average, Standard Deviation, Coeff. Var., average, standard deviation, coefficient variation) for each plate and an EC50 value for the entire assay. The grey cells in In the table below, the light grey shading for plate 1 are cells values from wells that do not contain the CHO Hamster cells. NHK cells. The dark grey shading represents the column and row location within the 96-well plate, and in this example the applicant chose to use these column and row locations to assign their REFID values in the RELREF dataset and GT dataset. For brevity, the datasets in this example are not comprehensive but are intended to demonstrate a range of proper use.
Neutral Red Cytotoxicity Assay Results (Relative Absorbance Data |
Neutral Red Cytotoxicity Assay Results (Relative Absorbance Data) |
|
|
| Sample ID | Smoke Regime | Replicate Number | Plate Number |
Well Number |
|
| Relative Assay Plate Absorbance Readings |
|
|
|
| Cigarette Smoke Condensate (µg/mL) | SLS (µg/mL) |
| EC50 (µg/ml) |
0 | 10 | Well Column: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Well
Row: | 0 | 10 | 50 | 75 | 100 | 120 | 140 | 160 | 200 | 110 | 200 | 0 |
|
| 030001 | Medium | 1 | 1 |
1A | 0.046*
| 0.046* | 0.039* | 0.012* | 0.030* | 0.003* | 0.057* | 0.032* | 0.003* | 0.050* | 0.044* | 0.040* |
|
| 030001 | Medium | 1 | 1 |
2B | 0.048* | 107 | 77.7 | 65.7 | 30.2 | 15.6 | 9.79 | 5.41 | 2.49 | 8.09 | 0.791 | 0.014* |
|
| 030001 | Medium | 1 | 1 |
3C | 0.005* | 98.6 | 77.4 | 57.7 | 35.8 | 8.09 | 7.36 | 3.22 | 0.791 | 6.38 | 0.061 | 0.050* |
|
| 030001 | Medium | 1 | 1 |
4D | 0.049* | 94.9 | 81.5 | 38.2 | 31.2 | 7.60 | 5.17 | 3.22 | 0.791 | 5.17 | 0.304 | 0.017* |
|
| 030001 | Medium | 1 | 1 |
5E | 0.047* | 111 | 78.1 | 64.5 | 32.9 | 8.82 | 5.90 | 2.74 | 1.28 | 10.3 | 0.547 | 0.011* |
|
| 030001 | Medium | 1 | 1 |
6F | 0.032* | 96.6 | 76.2 | 48.0 | 26.8 | 7.84 | 4.20 | 2.74 | 1.52 | 8.09 | 4.93 | 0.022* |
|
| 030001 | Medium | 1 | 1 |
7G | 0.044* | 105 | 77.9 | 58.2 | 28.3 | 8.09 | 4.68 | 1.76 | 0.547 | 8.57 | 1.76 | 0.056* |
|
| 030001 | Medium | 1 | 1 |
8H | 0.056* | 0.013* | 0.040* | 0.008* | 0.013* | 0.002* | 0.029* | 0.018* | 0.006* | 0.016* | 0.024* | 0.046* |
| Average |
| 101 | 78.2 | 54.5 | 29.9 | 9.70 | 6.17 | 3.37 | 1.19 | 8.94 | 1.22 |
|
| Std. Dev. |
| 6 | 2.9 | 9.4 | 3.6 | 2.95 | 2.19 | 1.12 | 0.72 | 2.72 | 1.58 |
|
| Coeff. Var. |
| 5.8 | 3.6 | 17.2 | 11.9 | 30.4 | 35.5 | 33.1 | 61.0 | 30.5 | 129.9 |
|
| *media without cells |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 030001 | Medium | 1 | 2 |
1A |
| 93.4 | 74.0 | 56.0 | 35.1 | 11.8 | 8.70 | 5.10 | 1.98 | 5.34 | 1.02 |
|
|
| 030001 | Medium | 1 | 2 |
2B |
| 102 | 75.2 | 53.3 | 35.1 | 11.8 | 7.74 | 5.58 | 3.66 | 5.34 | 1.02 |
|
|
| 030001 | Medium | 1 | 2 |
3C |
| 107 | 79.0 | 55.0 | 26.5 | 10.1 | 6.06 | 3.66 | 1.74 | 7.02 | 0.780 |
|
|
| 030001 | Medium | 1 | 2 |
4D |
| 104 | 80.2 | 55.3 | 29.8 | 8.94 | 3.90 | 3.66 | 1.50 | 6.30 | 0.780 |
|
|
| 030001 | Medium | 1 | 2 |
5E |
| 101 | 75.7 | 54.1 | 26.7 | 4.86 | 4.38 | 1.26 | 1.02 | 6.30 | 1.02 |
|
|
| 030001 | Medium | 1 | 2 |
6F |
| 110 | 85.7 | 67.7 | 26.0 | 5.34 | 4.62 | 3.42 | 1.50 | 6.30 | 0.540 |
|
|
| 030001 | Medium | 1 | 2 |
7G |
| 104 | 77.8 | 64.9 | 27.7 | 8.22 | 3.18 | 2.46 | 1.02 | 6.30 | 0.780 |
|
|
| 030001 | Medium | 1 | 2 |
8H |
| 103 | 71.6 | 58.9 | 25.5 | 9.42 | 4.14 | 3.90 | 1.26 | 4.38 | 0.780 |
|
| Average |
| 103 | 77.4 | 58.1 | 29.0 | 8.82 | 5.34 | 3.63 | 1.71 | 5.91 | 0.840 |
|
| Std. Dev. |
| 5 | 4.4 | 5.3 | 4.0 | 2.63 | 1.97 | 1.37 | 0.86 | 0.83 | 0.170 |
|
| Coeff. Var. |
| 4.6 | 5.6 | 9.2 | 13.6 | 29.8 | 36.9 | 37.6 | 50.0 | 14.1 | 20.2 |
|
| EC50 (µg/ml). Effective concentration at 50% cytotoxicity. (using a specific sigmoidal equation = model). |
(could also be EC20 or EC30, EC70, etc.)123 | |
| datasetdataset-wrap |
|---|
| Rowcaps |
|---|
| Rows 1-2: | Show | two | 2 records for TSPARMCD = "GLPTYP", using TSSEQ to indicate multiple records, since both GLP | Types | types apply for this example study. | | Row | 8| 3: | Shows that | the sponsor's study reference ID is not applicable| this study was conducted as a GLP study. | | Rows 4-5: | Show the study start date and study title. | | Rows | 9| 6- | 12| 7: | Show | that TSGRPID has been used to link records (name, location, country) related to the test facility | the version of SEND Implementation Guide and version of Controlled Terminology used in this study. | | Row 8: | Shows the applicant's organization. | | Row 9: | Shows that the applicant's study reference ID is not applicable. | | Rows 10-13: | Show that TSGRPID has been used to link records (name, location, country) related to the test facility (TSGRPID = 1). The | Study Director | study director is associated with the | Test Facility| test facility. | | Rows 14-16: | Show that TSGRPID (TSGRPID=4) has been used to link the information on the testing guideline followed on this study (TSTGDNAM, TSTGDORG, TSTGDVER). | | Shows the study type for this study. | | Shows that this study includes a Neutral Red Uptake Assay. | | Rows 19-20: | Show that the species is human and the cell line is NHK in this study. |
|
| Dataset2 |
|---|
| Dataset2 |
|---|
Row | STUDYID | ASSAYID | DOMAIN | TSSEQ | TSGRPID | TSPARMCD | TSPARM | TSVAL | | Row | STUDYID | DOMAIN | TSSEQ | TSGRPID | TSPARMCD | TSPARM | TSVAL |
|---|
NRU | | TS | 1 |
| GLPTYP | Good Laboratory Practice Type | FDA |
| | 2 | 123 |
NRU | | TS | 2 |
| GLPTYP | Good Laboratory Practice Type | OECD |
| | 3 | 123 |
NRU| TS | 1 |
| GLPFL | GLP Flag | Y |
| | 4 | 123 | TS | 1 |
| STSTDTC | Study Start Date | 2022-05-25 |
4NRU | | TS | 1 |
| STITLE | Study Title | Determination of the in vitro genotoxicity potential using the in vitro Neutral Red Uptake assay |
5NRU | TS | 1 |
| SNDIGVER | SEND Implementation Guide Version | TOBACCO IMPLEMENTATION GUIDE VERSION 1.0 |
6NRU | | TS | 1 |
| SNDCTVER | SEND Controlled Terminology Version | SEND Terminology 2021-09-30 |
7NRUSSPONSORSponsor Organization Sponsor 8NRUSPREFIDSponsor | Applicant Study Reference ID |
| NOT APPLICABLE |
9NRU | | TS | 1 | 1 | TSTFNAM | Test Facility Name | Example Test Lab Name |
10NRU | TS | 1 | 1 | TSTFLOC | Test Facility Location | 10 Somewhere Street, Montgomery, AL 10000 |
11NRU | | TS | 1 | 1 | TFCNTRY | Test Facility Country | USA |
12NRU | TS | 1 | 1 | STDIR | Study Director | Dr. R. Smith |
13NRUGLPFLGLP Flag | Y | 14 | 123 | NRU | TS | 1 | ASTD | Assay Standard | NIH | TSTGDNAM | Testing Guideline Name |
| Publication No. 07-4519 |
| | 15 | 123 |
NRU | ASTDV | | 4 | TSTGDORG | Testing Guideline Organization | NIH |
| | 16 | 123 | TS | 1 | 4 | TSTGDVER | Testing Guideline |
Assay Standard 16NRU | | TS | 1 |
| SSTYP | Study Type | GENOTOXICITY IN VITRO |
17NRUSSSTYP | Study Sub Type | In Vitro Neutral Red Uptake |
| GNTXAID | Genetic Toxicology Assay Identifier | NRU |
| | 19 |
18NRU | Hamster19NRU | TESTSYSTest SystemCHO |
|
| Dataset wrap |
|---|
| Rowcaps |
|---|
20| 12: | Show the test conditions for the set with a short name or SETCD value of |
CSC-50b sponsor | applicant chose this value to represent |
plate number 1, well number 1, with a concentration of 50µg/mLof Cigarette Smoke Condensate as shown in the report table for study 123.Row 17: | Shows the value for STRAIN/SUBSTRAIN is NO STRAIN because the well is a media only well, having no CHO Hamster cells| test conditions for the entire assay. | | Rows |
2140| 31: | Show the test conditions for the set with a short name or SETCD value of CSC- |
50 sponsor | applicant chose this value to represent plate number 1, well |
number 2, with | row A, well column 3, with a concentration of 50µg/mLof |
Cigarette Smoke Condensate | cigarette smoke condensate as shown in the report table for study 123. The value for Cell Line (CELLLN) is not applicable because the well is a media-only well, having no NHK cells. | Rows |
416050: | Show the test conditions for the set with a short name or SETCD value of CSC-50. |
sponsor | applicant chose this value to represent |
both wells numbered 7 in | plate number 1, well rows B-G, well column 3 and plate number 2 |
, with a concentration of 110µg/mLof Sodium Laurel Sulfate as shown in the report table for study 123| , well rows A-H, well column 3. These all have the concentration of 50µg/mLof cigarette smoke condensate as shown in the report table for study 123. | | Rows 51-69: | Show the test conditions for the set with a short name or SETCD value of SLS-110. The applicant chose this value to represent plate number 1, well rows B-G, well column 10, and plate number 2, well rows A-H, well column 10. These all have the concentration of 110µg/mLof sodium laurel sulfate as shown in the report table for study 123. |
|
| Dataset2 |
|---|
| ROW | STUDYID | DOMAIN | SETCD | SET | TXSEQ | TXPARMCD | TXPARM | TXVAL |
|---|
| 1 | 123 | TX | NRU | NRU_ASSAY | 1 | IVTDMIN | In vitro Treatment Duration Minimum | 47.5 | | 2 | 123 | TX | NRU | NRU_ASSAY | 2 | IVTDTRG | In vitro Treatment Duration Target | 48 | | 3 | 123 | TX | NRU | NRU_ASSAY | 3 | IVTDMAX | In vitro Treatment Duration Maximum | 48.5 | | 4 | 123 | TX | NRU | NRU_ASSAY | 4 | IVTDU | In vitro Treatment Duration Unit | HOURS | | 5 | 123 | TX | NRU | NRU_ASSAY | 5 | INCBTMP | Incubation Temperature | 37 | | 6 | 123 | TX | NRU | NRU_ASSAY | 6 | INCBTMPU | Incubation Temperature Unit | C | | 7 | 123 | TX | NRU | NRU_ASSAY | 7 | SWAVENM | Spectrophotometer Wavelength | 540 | | 8 | 123 | TX | NRU | NRU_ASSAY | 8 | ATMRHP | Atmospheric Relative Humidity Percent | 90 | | 9 | 123 | TX | NRU | NRU_ASSAY | 9 | ATMCO2P | Atmospheric CO2 Percent | 5 | | 10 | 123 | TX | NRU | NRU_ASSAY | 10 | SPDEVID | applicant defined device identifier | PUFFMASTER3k | | 11 | 123 | TX | NRU | NRU_ASSAY | 11 | SMKRGM | Smoking Regimen | MEDIUM INTENSITY REGIMEN | | 12 | 123 | TX | NRU | NRU_ASSAY | 12 | SPTOBID | Applicant-defined tobacco identifier | CIG01a | | 13 | 123 |
| | Dataset2 |
|---|
| Row | STUDYID | ASSAYID | DOMAIN | SETCD | SET | TXSEQ | TXPARMCD | TXPARM | TXVAL |
|---|
1 | 123 | NRU1TRTDMIN| IVTDMIN | In vitro Treatment Duration Minimum | 47.5 |
2NRU | 2TRTDTRG| IVTDTRG | In vitro Treatment Duration Target | 48 |
3NRU3TRTDMAX| IVTDMAX | In vitro Treatment Duration Maximum | 48.5 |
4NRU4TRTDU| IVTDU | In vitro Treatment Duration Unit | HOURS |
5NRU | 5| 17 | INCBTMP | Incubation Temperature | 37 |
6NRU | 6| 18 | INCBTMPU | Incubation Temperature Unit | C |
7NRU | 7WAVELGTH wavelength in nanometers8NRU | 8HUMID| ATMRHP | Atmospheric Relative Humidity Percent | 90 |
9NRU9ATMCO2| ATMCO2P | Atmospheric CO2 Percent |
5 | | 10 | 123 | NRU | TX | CSC-50b | CSC-50-blank | 10 | SPTOBID | Sponsor defined tobacco identifier | CIG01a | 11 | 123 | NRU11EXPTYP | Exposure Type | Air Liquid Interface | 12| SPDEVID | applicant defined device identifier | PUFFMASTER3k | | 23 | 123 |
NRU | 12SAMTYPSample Type | Whole Smoke Conditioned Media | | Smoking Regimen | MEDIUM INTENSITY REGIMEN | | 24 | 123 |
13 | 123 | NRU13INTRVN | Name of the Intervention Article | Tobacco ProdA | | SPTOBID | Applicant-defined tobacco identifier | CIG01a | | 25 | 123 |
14 | 123 | NRU14ITVTYPE | type of intervention article | PRODUCT | | EXPTYP | Exposure Type | Air Liquid Interface | | 26 |
15NRU | 15ITVCONCintervention concentration | 50 | | Sample Type | Whole Smoke Conditioned Media | | 27 |
16NRU | 16ITVCONCU | intervention unit | ug/ml | | ITVNAM | Name of the Intervention Article | Tobacco ProdA | | 28 |
17NRU | 17STRAIN | Strain/Substrain | NO STRAIN | | ITVTYPE | Intervention Article Type | PRODUCT | | 29 |
18NRU | 18SPDEVID | Sponsor defined device identifier | PUFFMASTER3k | | ITVCONC | Intervention Article Concentration | 50 | | 30 | 123 |
19 | 123 | NRU19DUREFID | Smoking Regime | Medium Intensity Regimen | | ITVCONCU | Intervention Article Concentration Unit | ug/ml | | 31 |
20NRU | 20SPTOBID | Sponsor defined tobacco identifier | CIG01a | | CELLLN | Cell Line | NOT APPLICABLE | | 32 | 123 |
21 | 123 | NRU1TRTDMIN| IVTDMIN | In vitro Treatment Duration Minimum | 47.5 |
22NRU | 2TRTDTRG| IVTDTRG | In vitro Treatment Duration Target | 48 |
23NRU | 3TRTDMAX| IVTDMAX | In vitro Treatment Duration Maximum | 48.5 |
24NRU4TRTDU| IVTDU | In vitro Treatment Duration Unit | HOURS |
25NRU | 5| 36 | INCBTMP | Incubation Temperature | 37 |
26NRU | 6| 37 | INCBTMPU | Incubation Temperature Unit | C |
27NRU | 7WAVELGTH wavelength in nanometers28NRU | 8HUMID| ATMRHP | Atmospheric Relative Humidity Percent | 90 |
29NRU | 9ATMCO2| ATMCO2P | Atmospheric CO2 Percent | 5 |
| 30 | 123 | NRU | TX | CSC-50 | CSC-50 | 10 | SPTOBID | Sponsor defined tobacco identifier | CIG01a | 31 | 123 | NRU11EXPTYP | Exposure Type | Air Liquid Interface | | SPDEVID | applicant defined device identifier | PUFFMASTER3k | | 42 |
32NRU | 12SAMTYPSample Type | Whole Smoke Conditioned Media | | Smoking Regimen | MEDIUM INTENSITY REGIMEN | | 43 | 123 |
33 | 123 | NRU13INTRVN | Name of the Intervention Article | Tobacco ProdA | | SPTOBID | Applicant-defined tobacco identifier | CIG01a | | 44 |
34NRU | 14ITVTYPE | type of intervention article | PRODUCT | | EXPTYP | Exposure Type | Air Liquid Interface | | 45 |
35NRU | 15ITVCONCintervention concentration | 50 | | Sample Type | Whole Smoke Conditioned Media | | 46 |
36NRU | 16ITVCONCU | intervention unit | ug/ml | 37 | 123 | | ITVNAM | Intervention Article Name | Tobacco ProdA | | 47 | 123 |
NRU17STRAIN | Strain/Substrain | CHO | 38 | 123 | | ITVTYPE | Intervention Article Type | PRODUCT | | 48 | 123 |
NRU18SPDEVID | Sponsor defined device identifier | PUFFMASTER3k | | ITVCONC | Intervention Article Concentration | 50 | | 49 |
39NRU | 19DUREFID | Smoking Regime | Medium Intensity Regimen | | ITVCONCU | Intervention Article Concentration Unit | ug/ml | | 50 | 123 |
40 | 123 | NRU20SPTOBID | Sponsor defined tobacco identifier | CIG01a | 41NRU | 1TRTDMIN| IVTDMIN | In vitro Treatment Duration Minimum | 47.5 |
42NRU2TRTDTRG| IVTDTRG | In vitro Treatment Duration Target | 48 |
43NRU | 3TRTDMAX| IVTDMAX | In vitro Treatment Duration Maximum | 48.5 |
44NRU4TRTDU| IVTDU | In vitro Treatment Duration Unit | HOURS |
45NRU5| 55 | INCBTMP | Incubation Temperature | 37 |
46NRU6| 56 | INCBTMPU | Incubation Temperature Unit | C |
47NRU | 7WAVELGTH wavelength in nanometers48NRU | 8HUMID| ATMRHP | Atmospheric Relative Humidity Percent | 90 |
49NRU | 9ATMCO2| ATMCO2P | Atmospheric CO2 Percent | 5 |
50NRU | 10SPTOBIDSponsor tobacco identifierCIG01a | | device identifier | PUFFMASTER3k | | 61 | 123 |
| 51 | 123 | NRU | TX | SLS-110 | SLS-110 | 11 | EXPTYP | Exposure Type | Air Liquid Interface | 52 | 123 | NRU12SAMTYPSample Type | Liquid | | Smoking Regimen | MEDIUM INTENSITY REGIMEN | | 62 |
53NRU | 13INTRVN | Name of the Intervention Article | Sodium Laurel Sulfate | | SPTOBID | Applicant-defined tobacco identifier | CIG01a | | 63 |
54NRU | 14ITVTYPE | type of intervention article | POSITIVE CONTROL | | EXPTYP | Exposure Type | Air Liquid Interface | | 64 | 123 |
55 | 123 | NRU15ITVCONCintervention concentration20056NRU | 16ITVCONCU | intervention unit | ug/ml | | ITVNAM | Intervention Article Name | Sodium Laurel Sulfate | | 66 |
57NRU | 17STRAIN | Strain/Substrain | CHO | | ITVTYPE | Intervention Article Type | POSITIVE CONTROL | | 67 |
58NRU | 18SPDEVID | Sponsor defined device identifier | PUFFMASTER3k | | ITVCONC | Intervention Article Concentration | | | 68 |
59NRU | 19DUREFID | Smoking Regime | Medium Intensity Regimen | | ITVCONCU | Intervention Article Concentration Unit | ug/ml | | 69 |
60NRU | 20SPTOBID | Sponsor defined tobacco identifier | CIG01a | |
|
| Dataset wrap |
|---|
|
The applicant chose to define the REFID values to indicate the Plate, the Column, and the Row of the wells of the 96-well plate in use, such that the well on plate 2, column 10, row G would assigned a REFID of 2-10-G. |
| Dataset wrap |
|---|
| Name | relref| Rowcaps |
|---|
| Row 1: | Shows the REFID of 123NRU that indicates the entire assay. | | Rows 2, 5, 8, 9:-4: | Show the REFIDs at the second level, all within the parent assay of 123NRU (REFID values of 1-3b, 1-3, 1-10, 2-10). | | Rows 3-4, 6-7, 10-11: | Show REFID values that the sponsor chose, in this case, to represent the plate number (1 or 2), column (1 - 10), and row (A-G) of the 96-well plate. | | at the second level, all within the parent assay of 123NRU (REFID values of 1-3, 1-10, 2-10) which have LVLDESC of OBSERVATIONAL SUMMARY. If this study had recorded summary statistics for an entire trial set (e.g., across both plates for the same dose level), there would be an additional REFID for the trial set (with a LVLDESC of TRIAL SET). | | Rows 5-6: | Show the REFIDs 1-3-A and 1-3-H that indicate two experimental units that are also observational units within the SETCD of CSC-50b that have the parent REFID of 123NRU. | | Rows 7-8Rows 3-4: | Show the REFIDs 1-3-A B and 1-3-H C that indicate two experimental units that are also observational units within the SETCD of CSC-50 that have the parent Trial Set REFID of 1-3b3. | | Rows 6-7Row 9: | Show Shows the REFIDs REFID of 1-3-B and 1-3-C that indicate two experimental units within the parent Trial Set of 1-3b.10-G that indicates the experimental unit that is also an observational unit within the SETCD of SLS-110 that has the parent REFID of 1-10. | | Row 10: | Shows the REFID of 2-10-G that indicates the experimental unit that is also an observational unit within the SETCD of SLS-110 that has the parent REFID of 2-10 | Rows 10-11: | Show the REFIDs 1-10-G and 2-10-G that indicate two experimental units within the parent Trial Set of 1-3b. |
|
| Dataset2 |
|---|
| ASSAYID | SETCD | REFID | PARENT | LEVEL | LVLDESC |
|---|
| 1 | 123 | |
ALL | NRU | 50b3bTRIAL SETCSC| OBSERVATIONAL SUMMARY | | 3 | 123 |
NRU | 50b3-A1-3b | 3 | EXPERIMENTAL UNITCSC| 10 | 123NRU | 2 | OBSERVATIONAL SUMMARY | | 4 | 123 |
NRU | 50b13-H1-3b | 3 | EXPERIMENTAL UNIT| 10 | 123NRU | 2 | OBSERVATIONAL SUMMARY | | 5 | 123 |
NRU | 50TRIAL SET| EXPERIMENTAL UNIT/OBSERVATIONAL UNIT | | 6 | 123 |
NRU | 50B1-33| 2 | EXPERIMENTAL UNIT/OBSERVATIONAL UNIT | | 7 | 123 |
NRU | C | 3 | EXPERIMENTAL UNIT/OBSERVATIONAL UNIT | | 8 | 123 | CSC-50 | 1-3-C | 1-3 |
3 | EXPERIMENTAL UNIT | | 8 | 123 | NRU | SLS-110 | 1-10 | 123NRU | 2 | TRIAL SET | | 9 | 123 | NRU | SLS-110 | 2-10 | 123NRU | 2 | TRIAL SET | 10 | 123 | NRU | SLS-110 | 1-10-G | 1-10 | 3 | EXPERIMENTAL UNIT/OBSERVATIONAL UNIT |
11NRU | 22| 1-10 | 3 | EXPERIMENTAL UNIT/OBSERVATIONAL UNIT |
|
|
|---|
dataset-wrap| 10 | 123 | SLS-110 | 2-10-G | 2-10 | 3 | EXPERIMENTAL UNIT/OBSERVATIONAL UNIT |
|
|
| Dataset wrap |
|---|
|
Certain |
|
| Rowcaps |
|---|
|
| Rows 1-3: | Show the experimental unit data for REFID 1-3-B. |
Rows 1-2, 4-5, 10-11, 16-17: | These data (Absorbance Reading and Background Corrected Absorbance Reading) are not shown in the sample report table above but are included here for completeness of the NRU assay.
| Rowcaps |
|---|
| Rows 1-3: | Show the experimental unit data for GTREFID 1-3-B. | | Rows 4-6: | Show the experimental unit data for REFID GTREFID 1-3-C. | | Rows 7-9: | Show the data for the entire trial set, REFIDGTREFID=1-3. | | Rows 10-12: | Show the experimental unit data for REFID GTREFID 1-10-G | | Rows 13-15: | Show the data for the entire trial set, REFIDGTREFID=1-10 | | Rows 16-18: | Show the experimental unit data for REFID GTREFID 2-10-G. | | Rows 19-21: | Show the data for the entire trial set, REFIDGTREFID=2-10 | | Row 22: | Shows the data for the entire assay, REFIDGTREFID=123NRU. |
|
| Dataset2 |
|---|
ASSAYIDREFID| GTREFID | GTTESTCD | GTTEST | GTORRES | GTORRESU | GTCOLSRT | GTSTRESC | GTSTRESN | GTSTRESU |
|---|
| 1 | 123 |
NRU | | GT | 1 | 1-3-B | ABSORB | Absorbance Reading | 1.7 |
|
| 1.7 | 1.7 |
| | 2 | 123 |
NRU | GT | 2 | 1-3-B | BKCABS | Background Corrected Absorbance Reading | 1.6 |
|
| 1.6 | 1.6 |
| | 3 | 123 |
NRU | | GT | 3 | 1-3-B | RELABS | Relative Absorbance Reading | 77.7 |
% | % | NRU | | GT | 4 | 1-3-C | ABSORB | Absorbance Reading | 1.8 |
|
| 1.8 | 1.8 |
| | 5 | 123 |
NRU | | GT | 5 | 1-3-C | BKCABS | Background Corrected Absorbance Reading | 1.7 |
|
| 1.7 | 1.7 |
| | 6 | 123 |
NRU | GT | 6 | 1-3-C | RELABS | Relative Absorbance Reading | 77.4 |
|
| 77.4 | 77.4 |
| | 7 | 123 |
NRU | | GT | 7 | 1-3 | RELABS | Relative Absorbance Reading | 78.2 | % | MEAN | 78.2 | 78.2 | % | | 8 | 123 |
NRU | | GT | 8 | 1-3 | RELABS | Relative Absorbance Reading | 2.9 | % | STANDARD DEVIATION | 2.9 | 2.9 | % | | 9 | 123 |
NRU | | GT | 9 | 1-3 | RELABS | Relative Absorbance Reading | 3.6 |
| COEFFICIENT OF VARIANCE | 3.6 | 3.6 |
| | 10 | 123 |
NRU | | GT | 10 | 1-10-G | ABSORB | Absorbance Reading | 0.7 |
|
| 0.7 | 0.7 |
| | 123 |
NRU | GT | 11 | 1-10-G | BKCABS | Background Corrected Absorbance Reading | 0.6 |
|
| 0.6 | 0.6 |
| | 12 | 123 |
NRU11| 12 | 1-10-G | RELABS | Relative Absorbance Reading | 8.57 |
|
| 8.57 | 8.57 |
| | 13 | 123 |
NRU | 12| 13 | 1-10 | RELABS | Relative Absorbance Reading | 8.94 | % | MEAN | 8.94 | 8.94 |
| | 14 | 123 |
NRU13| 14 | 1-10 | RELABS | Relative Absorbance Reading | 2.72 | % | STANDARD DEVIATION | 2.72 | 2.72 |
| | 15 | 123 |
NRU14| 15 | 1-10 | RELABS | Relative Absorbance Reading | 30.5 |
| COEFFICIENT OF VARIANCE | 30.5 | 30.5 |
| | 16 | 123 |
NRU | 15| 16 | 2-10-G | ABSORB | Absorbance Reading | 0.9 |
|
|
|
|
| | 17 | 123 |
NRU | 16| 17 | 2-10-G | BKCABS | Background Corrected Absorbance Reading | 0.8 |
|
|
|
|
| | 18 | 123 |
NRU | 17| 18 | 2-10-G | RELABS | Relative Absorbance Reading | 6.30 |
|
| 6.30 | 6.30 |
| | 19 | 123 |
NRU | 18| 19 | 2-10 | RELABS | Relative Absorbance Reading | 5.91 | % | MEAN | 5.91 | 5.91 |
| | 20 | 123 |
NRU | 19| 20 | 2-10 | RELABS | Relative Absorbance Reading | 0.83 | % | STANDARD DEVIATION | 0.83 | 0.83 |
| | 21 | 123 |
NRU20| 21 | 2-10 | RELABS | Relative Absorbance Reading | 14.1 |
| COEFFICIENT OF VARIANCE | 14.1 | 14.1 |
| | 22 | 123 |
NRU | 21EC50 | Effective Concentration of 50 Percent Cytotoxicity | 123 | ug/ml |
| 123 | 123 | ug/ml |
|